| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/04/2011 | CA2445251C Crystalline form of omeprazole |
| 01/04/2011 | CA2429312C Novel pyridine-substituted pyrazolopyridine derivatives |
| 01/04/2011 | CA2427750C Substituted alkanoic acids |
| 01/04/2011 | CA2419423C Conjugates of peptides and peptide mimetics having integrin inhibitor properties |
| 01/04/2011 | CA2416274C N-phenyl-2-pyrimidine-amine derivatives |
| 01/04/2011 | CA2413426C Methods and compositions utilizing quinazolinones |
| 01/04/2011 | CA2412941C Piperidine compounds for use as ccr-3 inhibitors |
| 01/04/2011 | CA2411204C Composition and method |
| 01/04/2011 | CA2404128C Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 01/04/2011 | CA2401545C Mutated cyclin g1 protein |
| 01/04/2011 | CA2389206C Activation of hcv-specific t cells |
| 01/04/2011 | CA2375008C Phenoxypropylamine compounds |
| 01/04/2011 | CA2365085C Therapeutic agents for diabetes |
| 01/04/2011 | CA2319672C Compounds and compositions for delivering active agents |
| 01/04/2011 | CA2317505C Enzyme catalyzed therapeutic agents |
| 01/04/2011 | CA2306875C Nutritional supplement for cerebral metabolic insufficiencies |
| 01/04/2011 | CA2163439C Methods of using bcl-2 for the therapeutic treatment and prevention of diseases |
| 12/30/2010 | US20100331928 Visible light modulation of mitochondrial function in hypoxia and disease |
| 12/30/2010 | US20100331414 Crystal comprising (2r)-2-propyloctanoic acid and amine |
| 12/30/2010 | US20100331349 Use of gamma-aminobutyric acid to mask or reduce an unpleasant flavour impression and preparations containing gamma-aminobutyric |
| 12/30/2010 | US20100331329 Benzamide derivatives useful as histone deacetylase inhibitors |
| 12/30/2010 | US20100331266 Analysis of amino acid copolymer compositions |
| 12/30/2010 | US20100331254 Pulverized fibrin clots and pharmaceutical compositions containing them |
| 12/30/2010 | US20100331253 Method for cell adhesion and wound healing |
| 12/30/2010 | US20100331236 Cyclic peptides as g-protein coupled receptor antagonists |
| 12/30/2010 | US20100330203 Method for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition prepared on-site |
| 12/30/2010 | US20100330197 Oral or enteral composition useful for recovery of physical functions |
| 12/30/2010 | US20100330165 Use of chemotherapeutic agents |
| 12/30/2010 | US20100330144 Methods and Apparatus for Fabricating Porous Three-Dimensional Tubular Scaffolds |
| 12/30/2010 | US20100330117 Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis, non-viral based cancers, alzheimers's disease, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis, west nile virus, fibromyalgia, shingles, gout, migraine headaches, senile dementia, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c |
| 12/30/2010 | US20100330110 Therapeutic and diagnostic uses of antibody specificity profiles |
| 12/30/2010 | US20100330083 Plasminogen activator variant formulations |
| 12/30/2010 | US20100330080 Antigen binding polypeptides |
| 12/30/2010 | US20100330039 Schizochytrium Fatty Acid Synthase (FAS) and Products and Methods Related Thereto |
| 12/30/2010 | US20100330037 Adenoviral systems and the uses thereof |
| 12/30/2010 | US20100329997 Use of creatine or creatine compounds for skin preservation |
| 12/30/2010 | US20100329991 Medicinal preparation particularly for the treatment of slipped discs hernias |
| 12/30/2010 | US20100329988 Method for Identifying Within a Mammal a DNA Encoding A Physiologically Active Polypeptide |
| 12/30/2010 | US20100329976 Nanoparticulate compositions of angiogenesis inhibitors |
| 12/29/2010 | WO2010151020A2 Fast-dissolving oral film for effectively concealing unpleasant tastes |
| 12/29/2010 | WO2010150899A1 Novel thiophene carboxamide derivative and medicinal use of same |
| 12/29/2010 | WO2010150865A1 Crystals |
| 12/29/2010 | WO2010150840A1 N-substituted-cyclic amino derivative |
| 12/29/2010 | WO2010150837A1 Indoline derivative |
| 12/29/2010 | WO2010150836A1 Enhancer of activity of nucleic acid analogue |
| 12/29/2010 | WO2010150819A1 Therapeutic agent for ischemic cerebrovascular disorders |
| 12/29/2010 | WO2010150791A1 Process for production of adenosine tetraphosphate compound |
| 12/29/2010 | WO2010150739A1 Hydroxyl-containing pyripyropene derivatives exhibiting acat2-inhibitory activity |
| 12/29/2010 | WO2010150538A1 Drug for inhibiting lectin-like oxidized ldl receptor and drug for preventing arteriosclerosis |
| 12/29/2010 | WO2010078730A9 Preparation of ginsenoside-rd propylene glycol aqueous solution and new use thereof in anti-inflammation, immunosuppression and anti organ-graft rejection |
| 12/29/2010 | EP2267454A2 Diagnosis and prevention of cancer cell invasion |
| 12/29/2010 | EP2267117A2 Differentiation modulating agents and uses therefor |
| 12/29/2010 | EP2267026A1 Albumin fusion proteins |
| 12/29/2010 | EP2266986A1 Cytotoxins, Prodrugs, Linkers and Stabilizers useful therefor |
| 12/29/2010 | EP2266978A1 Novel physiologically active substances |
| 12/29/2010 | EP2266970A1 Substituted aromatic heterocyclic compounds as fungicides |
| 12/29/2010 | EP2266968A2 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
| 12/29/2010 | EP2266960A2 Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants |
| 12/29/2010 | EP2266958A1 Antiviral agent |
| 12/29/2010 | EP2266665A1 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 12/29/2010 | EP2266627A1 Single-stranded oligodeoxynucleotide mutational vectors |
| 12/29/2010 | EP2266624A2 Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections |
| 12/29/2010 | EP2266621A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 12/29/2010 | EP2266620A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 12/29/2010 | EP2266583A1 Gene expression inhibitor selective for matrix metalloproteinase-9 gene |
| 12/29/2010 | EP2266576A1 Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 12/29/2010 | EP2266566A2 Nicotinamide derivatives and their use as therapeutic agents |
| 12/29/2010 | EP2266564A1 Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist |
| 12/29/2010 | EP2266563A1 Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
| 12/29/2010 | EP2266559A1 Therapeutic agent for ophthalmic disease |
| 12/29/2010 | EP2266557A1 Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components |
| 12/29/2010 | EP2266552A2 Methods of inducing terminal differentiation |
| 12/29/2010 | EP2266548A2 Dry powder for inhalation |
| 12/29/2010 | EP2266540A1 Pharmaceutical compositions comprising a HMG COA reductase inhibitor |
| 12/29/2010 | EP2265269A1 Selective subtype alpha 2 adrenergic agents and methods for use thereof |
| 12/29/2010 | EP1530568B1 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING I&kB KINASE |
| 12/29/2010 | EP1529062B1 Therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signal transduction |
| 12/29/2010 | EP1494705B1 A composition and method for killing of tumours |
| 12/29/2010 | EP1487802B1 2,3-Diaryl-pyrazolidine derivatives as neurotensin degrading enzyme inhibitors |
| 12/29/2010 | EP1438052B1 Quinazolin-4-ones as inhibitors of human phosphatidylinositol 3-kinase delta |
| 12/29/2010 | EP1425305B1 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses |
| 12/29/2010 | EP1292573B1 Substituted thioacetamides |
| 12/29/2010 | EP1107722B1 A method for the treatment of staphylococcal infection |
| 12/29/2010 | EP1001946B1 QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES |
| 12/29/2010 | CN1968691B Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis |
| 12/29/2010 | CN1922139B Bicyclic amide derivatives |
| 12/29/2010 | CN1856504B Anti-infarction molecules |
| 12/29/2010 | CN101932584A Pyrrolopyrimidin derivative for use as pi3k inhibitor, and use thereof |
| 12/29/2010 | CN101932575A Piperidine derivative |
| 12/29/2010 | CN101932338A Method for determination of sensitivity to anti-cancer agent |
| 12/29/2010 | CN101932331A Methods for in vitro maturation of ovarian follicles |
| 12/29/2010 | CN101932320A Membrane fusion inhibitor |
| 12/29/2010 | CN101928692A Differentiated cells suitable for human therapy |
| 12/29/2010 | CN101928289A Method for preparing dipeptidyl peptidase-IV inhibitor |
| 12/29/2010 | CN101928288A Small molecule compositions for binding to HSP90 |
| 12/29/2010 | CN101928287A Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same |
| 12/29/2010 | CN101928284A Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| 12/29/2010 | CN101928281A Bicyclo-substituted pyrazolone azo derivative, preparation method thereof and application thereof in medicaments |
| 12/29/2010 | CN101928262A Biologically active methylene blue derivatives |
| 12/29/2010 | CN101928259A 2-arylthiazole derivative and medicament composition thereof |